| Hazard Information | Back Directory | [Uses]
Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy[1]. | [IC 50]
JNK1: 1.25 μM (IC50); JNK2: 1.07 μM (IC50); JNK3: 1.24 μM (IC50) | [References]
[1] Liu X, et al. Cyy-272, an indazole derivative, effectively mitigates obese cardiomyopathy as a JNK inhibitor. Biomed Pharmacother. 2024 Sep;178:117172. DOI:10.1016/j.biopha.2024.117172 |
|
|